Literature DB >> 17488689

P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.

Kyung-Hun Lee1, Sung Sup Park, Inho Kim, Jin Hee Kim, Eun Kyung Ra, Sung-Soo Yoon, Yun-Chul Hong, Seonyang Park, Byoung Kook Kim.   

Abstract

BACKGROUND AND OBJECTIVES: The P2X7 receptor (P2X7 R) is a key player in the processing and release of interleukin (IL)-1. To evaluate whether the A1513C polymorphism of the P2X7 R gene is related to allogeneic stem cell transplantation outcome, we performed an association analysis between this polymorphism and clinical outcomes in patients treated with an HLA-matched sibling stem cell transplant. DESIGN AND METHODS: Patients (n=152) with a malignancy or aplastic anemia underwent allogeneic stem cell transplantation at a single institute. Peripheral blood DNA of these 152 patients and their 152 donors was genotyped. Genotypes of 145 recipients and 150 donors were obtained and analyzed for the polymorphism.
RESULTS: The frequencies of the A and C alleles in all 295 study subjects were 72% and 28%, respectively. The genotypes in patients were AA in 75, AC in 58, and CC in 12; the genotypes in donors were AA in 74, AC in 70, and CC in 6. Overall survival was significantly shorter for recipients with the CC genotype than for those with the AA or AC genotype (92 days for 1513CC vs. 821 days for 1513AA or 1513AC, p=0.012), and for recipients from donors with the CC genotype than for recipients from donors with the AA or AC genotype (63 days for 1513CC vs. 702 days for 1513AA or 1513AC, p=0.024). Multivariate analyses, which included sex, age, transplant method (reduced intensity conditioning vs. conventional conditioning), stem cell source, risk group, and P2X7R recipient and donor genotypes, as parameters, identified high-risk group (hazard ratio 3.25, 95% confidence interval 1.83~5.77) and a donor 1513CC genotype (hazard ratio 2.66, 95% confidence interval 1.02~6.91) as risk factors for a shorter survival. Microbiologically documented bacteremia occurred in 66.7% of recipients with the CC donor genotype and in 17.6% of recipients of transplants of AA or AC genotype (p=0.014). INTERPRETATION AND
CONCLUSIONS: We conclude that the A1513C polymorphism in the P2X7R gene is related to the occurrence of infections and survival after allogeneic stem cell transplantation. Thus, the determination of this polymorphism may be helpful for the optimal selection of patients and donors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488689     DOI: 10.3324/haematol.10810

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  13 in total

1.  The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.

Authors:  N J Geraghty; L Belfiore; D Ly; S R Adhikary; S J Fuller; W Varikatt; M L Sanderson-Smith; V Sluyter; S I Alexander; R Sluyter; D Watson
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

Review 2.  Danger signals activating innate immunity in graft-versus-host disease.

Authors:  Robert Zeiser; Olaf Penack; Ernst Holler; Marco Idzko
Journal:  J Mol Med (Berl)       Date:  2011-05-15       Impact factor: 4.599

3.  Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.

Authors:  Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

4.  Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Authors:  Konrad Wilhelm; Jayanthi Ganesan; Tobias Müller; Christoph Dürr; Melanie Grimm; Andreas Beilhack; Christine D Krempl; Stephan Sorichter; Ulrike V Gerlach; Eva Jüttner; Alf Zerweck; Frank Gärtner; Patrizia Pellegatti; Francesco Di Virgilio; Davide Ferrari; Neeraja Kambham; Paul Fisch; Jürgen Finke; Marco Idzko; Robert Zeiser
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

5.  Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function.

Authors:  Chengqun Sun; Jessica Chu; Sarita Singh; Russell D Salter
Journal:  Purinergic Signal       Date:  2009-10-17       Impact factor: 3.765

Review 6.  Risk stratification and immunogenetic risk for infections following stem cell transplantation.

Authors:  Agnieszka Wójtowicz; Pierre-Yves Bochud
Journal:  Virulence       Date:  2016-09-09       Impact factor: 5.882

Review 7.  Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses.

Authors:  Yoshinobu Maeda
Journal:  Int J Hematol       Date:  2013-08-28       Impact factor: 2.490

8.  P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes.

Authors:  Francesca D'Addio; Andrea Vergani; Luciano Potena; Anna Maestroni; Vera Usuelli; Moufida Ben Nasr; Roberto Bassi; Sara Tezza; Sergio Dellepiane; Basset El Essawy; Maria Iascone; Attilio Iacovoni; Laura Borgese; Kaifeng Liu; Gary Visner; Sirano Dhe-Paganon; Domenico Corradi; Reza Abdi; Randall C Starling; Franco Folli; Gian Vincenzo Zuccotti; Mohamed H Sayegh; Peter S Heeger; Anil Chandraker; Francesco Grigioni; Paolo Fiorina
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

Review 9.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

Review 10.  Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review.

Authors:  Nicolas Waespe; Sven Strebel; Simona Jurkovic Mlakar; Maja Krajinovic; Claudia Elisabeth Kuehni; Tiago Nava; Marc Ansari
Journal:  J Pers Med       Date:  2021-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.